Altimmune Inc. (NASDAQ:ALT) price closed lower on Monday, September 13, dropping -1.43% below its previous close.
A look at the daily price movement shows that the last close reads $16.81, with intraday deals fluctuated between $16.3705 and $17.26. The company’s 5Y monthly beta was ticking 1.38. Taking into account the 52-week price action we note that the stock hit a 52-week high of $24.61 and 52-week low of $7.80. The stock added 40.07% on its value in the past month.
Altimmune Inc., which has a market valuation of $641.92 million, is expected to release its quarterly earnings report Nov 08, 2021 – Nov 12, 2021. Analysts tracking ALT have forecast the quarterly EPS to shrink by -0.39 per share this quarter, while the same analysts predict the annual EPS to hit -$1.77 for the year 2021 and up to -$1.79 for 2022. In this case, analysts estimate an annual EPS growth of 7.30% for the year and -1.10% for the next year.
Staying with the analyst view, there is a consensus estimate of $1.13 million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow -86.20% below that which the company brought in 2021.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give ALT a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 50% Buy.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 7 analysts have assigned ALT a recommendation rating as follows: 0 rate it as a Hold; 7 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Altimmune Inc. (ALT) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that ALT’s price is at present 16.74% off the SMA20 and 45.94% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 74.54, with weekly volatility standing at 4.78%. The indicator jumps to 6.40% when calculated based on the past 30 days. Altimmune Inc. (NASDAQ:ALT)’s beta value is holding at 1.70, while the average true range (ATR) indicator is currently reading 0.86. Considering analysts have assigned the stock a price target range of $25.00-$44.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $30.86. Based on this estimate, we see that current price is roughly -50.88% off the estimated low and -165.54% off the forecast high. Investors will no doubt be excited to see the share price fall to $30.00, which is the median consensus price, and at that level ALT would be -81.05% from current price.
An analysis of the Altimmune Inc. (NASDAQ:ALT) stock in terms of its daily trading volume indicates that the 3-month average is 2.00 million.
Current records show that the company has 41.36M in outstanding shares. The insiders’ percentage holdings are 0.80% of outstanding shares while the percentage share held by institutions stands at 70.10%. But the 46.90% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.